No CrossRef data available.
Article contents
Thrombolytic Therapy for Acute Ischemic Stroke: The CAEP Position Statement: another perspective
Published online by Cambridge University Press: 21 May 2015
Extract
The cautiously-worded Position Statement recently issued by the Canadian Association of Emergency Physicians (see Appendix 1) regarding the use of intravenous recombinant tissue-plasminogen activator (tPA, alteplase) for acute ischemic stroke underscores the reality that many physicians in Canada have been reluctant to embrace this therapy. Much of the caution expressed in the CAEP document is related to 2 major areas of concern: evidence of efficacy (i.e., did tPA really “prove” itself in randomized trials?) and effectiveness (i.e., are the trial results generalizable to everyday practice?). While we support the development of documents that help to clarify controversial treatments, and agree with much of what is presented in the CAEP Position Statement, we offer the following comments.
- Type
- Controversies • Controverses
- Information
- Copyright
- Copyright © Canadian Association of Emergency Physicians 2001